Research – ProMIS Neurosciences (PMN:CA) – Potential opportunity in Alzheimer’s

Thursday, March 21, 2019

ProMIS Neurosciences (PMN:CA)

A door opens in the treatment for Alzheimer’s.

ProMIS Neurosciences,
Inc., a development stage biotech company, discovers and develops precision
medicine therapeutics for the treatment of neurodegenerative diseases,
primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its
proprietary target discovery engine is based on the use of two complementary
techniques. 

Cosme Ordoñez, M.D., Ph. D.

, Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating. 

  • Competitor discontinues development. Biogen (BIIB: Not Rated), a competing company in the Alzheimer’s area,
    this morning announced the decision to discontinue clinical 
    development of aducanumab.  Biogen is
    discontinuing two Phase III clinical trials evaluating the efficacy and safety
    of 
    aducanumab for the treatment of Alzheimer’s patients. 
  • Skepticism to heighten. We believe the negative news will fuel skepticism among
    investors looking to deploy capital in Alzheimer’s area. The failure of Biogen
    adds to a string of disappointing results in hum…





    Get full report on Channelchek desktop.



*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

News – CRISPR-Cas9: Editing away sickness

CRISPR-Cas9: The
Gene Editing Tool That Could Fix Disease and Eradicate Cancer

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section) 

The discovery of a gene editing tool called CRISPR-Cas9 is perhaps the most exciting finding in molecular biology since the discovery of DNA. Scientists first unearthed the structure of DNA in the 1950s, and by 2003 scientists had sequenced the entire human genome encoding for 20,000 distinct proteins. Following its discovery in bacterial immune systems, CRISPR-Cas9 was first used to replace a piece of DNA in human cells in 2013. But it was only just last year that the CRISPR-Cas9 technology advanced into human trials to treat patients with various inherited diseases and cancers. With this newfound power to edit our own genes, we could be on the verge of a medical revolution.

Many human diseases are genetically driven often caused by the mutation, deletion, or overexpression of genes. Therefore, introducing desired changes into genes has been a long sought-after goal in molecular biology. Gene editing (also known as genome editing) involves the insertion, deletion, or replacement of those chemical base pairs in DNA. DNA (deoxyribonucleic acid), the building block of genes, is used to synthesize proteins via RNA (ribonucleic acid). Genomes of eukaryotic organisms are composed of billions of DNA bases. Cas9 is an enzyme acting as a molecular “scissors” that can cut the two strands of DNA at a specific location in the genome so that bits of DNA can then be added or removed. The guide RNA (gRNA) about 20 bases long is designed to only bind to the target sequence in the DNA. The Cas9 follows the guide RNA to the same location in the DNA sequence. In order to cut a piece of DNA at the right spot, the molecular “zipper” needs to accurately match up with the piece of the DNA to form a tight bond that positions the scissors in just the right place. In CRISPR, the “zipper” is made of specially designed RNA, and the “scissor” effect comes from harnessing the natural cutting action of a protein, or enzyme, called Cas9. In this way, CRISPR-Cas9 can insert, delete, or replace the genes that have plagued humanity with disease since the dawn of time.

Research – Trovagene (TROV) – 2018 full year update

Friday, March 8, 2019

Trovagene Inc. (TROV)

Focus on upcoming catalyst, 2018 earnings review and early 2019 developments.

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.  

  • Progressing clinical programs. The company continues to focus on
    advancement of its clinical programs. We have seen two clinical trials readouts
    up to date 1) from Phase 1b/2 acute myeloid leukemia (AML) study-
    demonstrating favorable clinical benefit (80% disease control rate) among 12
    acute myeloid leukemia (AML) patients and 2) from Phase 1/2 metastatic
    castration resistant prostate cancer (mCRPC) program- leading to dosing
    adjustments to extend drug exposure and clinical benefit in mCRPC patients.
  • Upcoming catalysts.  We are expecting to see a few key value generating
    events 1) further data readouts from Phase 1b/2 acute myeloid leukemia
    (AML) program at American Association for Cancer Research (AACR) annual
    meeting, 2) data readout f





    Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

News – Alzheimer’s, Cannibals, and the Scientist Who Saw the Connection

How does a Nobel Prize winner, the mystery of Alzheimer’s Disease, and a rare brain ailment caused by cannibalism become part of the same story?

(Note: related companies are at base
of the story and all the sources listed in the “Balanced” section)

In
1997, Dr. Stanley Prusiner won the Nobel Prize in Medicine and Physiology for
the discovery of the cause of Creutzfeld Jakob encephalopathy, a rare brain
disease caused by an infectious particle known as prion. The Prion particle is
also the cause of the Kuru disease, an ailment first observed among a tribe in
New Guinea, who practice cannibalistic rituals. Members of this tribe ate the
brains of the deceased as a result of their spiritual beliefs. Kuru disease is
characterized by the presence of tremors and other neurological symptoms.

In
recent years, medical scientists have discovered that the same type of
mechanism, a prion-like phenomenon, might also be related to the cause of
Alzheimer’s disease. Scientists have demonstrated that molecules derived from
amyloid-beta behave in a prion-like fashion. Last year, Cold Spring Harbor
Laboratories published a seminal review article by Dr. Stanley Prusiner
entitled “Amyloid-beta Prions and the Pathobiology of Alzheimer’s Disease” (see
sources below). In the article, Dr. Prusiner clearly explains how these
prion-like molecules are related to the cause of Alzheimer’s. Today, prions are
defined as alternative protein conformation capable of self-propagation.
Indeed, prion particles are infectious. They encipher their own replication
blueprint without the use of a genetic code. It is defined as protein-only
inheritance.

This
month, French scientists from Sorbonne
Université in Paris have published an article on the journal “Current Opinion
in Neurology” (article in press, see reference below) discussing the body of
evidence in the medical literature supporting the prion hypothesis as the cause
of Alzheimer’s. As Dr. Stanley Prusiner’s medical hypothesis gains acceptance
among medical scientists today, it almost becomes imperative to review the
history behind Dr. Prusiner’s eureka moment.
 

The Discovery of the Prion and The
Scientific Controversy that Ensued Afterward

In
1997, the Medicine and Physiology Nobel Prize Ceremony became vindication for a
maverick scientist who was marginalized by the scientific community for almost
15 years. The winner of the highly rewarded prize that year, Dr. Stanley
Prusiner, had been previously criticized for postulating a medical hypothesis
that challenged at the time one of the most important dogmas in biology. Back
then, it was widely accepted by the scientific establishment that the flow of
genetic information is based on the genetic code. Information flows from
nucleic acids, DNA and RNA, to proteins. The problem was that the Prion
particle did not contain any nucleic acid. With zero content of DNA or RNA, how
was it possible that Prions were infectious? Scientists were in disbelief.

On
his paper published on the journal “Science
in 1982, Dr. Prusiner claimed that the Prion particle, the infectious agent
that caused Creutzfeld Jakob disease, consisted of only protein, with zero
nucleic acid content. The scientific community did not believe Dr. Prusiner’s
findings. His medical hypothesis was rejected by most of his peers. Without any
nucleic acid content, a particle cannot be infectious, they sternly claimed. It
is not feasible as there is no genetic information within the Prion particle,
the medical community thought at the time. As a result of the discrepancy, the
work of Dr. Prusiner’s laboratory lost credibility, as scientists and experts
claimed that Dr. Prusiner’s team have failed to identify the presence of nucleic
acid in a Prion. The culprit of the infection had to be a nucleic acid,
scientists thought then. They were confident that the nucleic acid had gone
undetected by Prusiner’s team, maybe because it was in minor quantities.

Dr.
Prusiner denied those claims, as he sternly continued to support his medical
hypothesis:

The Prion particle consists
of only protein with two main properties:

  1. prions
    exist in two main conformations (“sick conformation with propensity to generate
    oligomerization or formation of aggregates, and normal conformation, which
    remains monomeric (single protein, without aggregation));
  2. The
    prion conformation (“sick” form of the protein) can propagate itself by
    converting the normal conformation of the protein into prion by physical
    contact.

The
controversy made Dr. Stanley Prusiner a pariah of the scientific community.
Organizers of medical conferences and meetings did not want to invite him, and
rumors of many kinds on the origin and quality of his work grew.

Cannibalism and the Infectious
Prion

Kuru is a rare, fatal brain disease caused by “funerary cannibalism”. The disease spread among the people of Papua New Guinea, an Oceanian country, where relatives consumed the bodies of the deceased. Their belief was that a “life force” of the dead will return to them. The spread of Kuru started in the region in the 1920s, becoming an epidemic lasting until 2009. Kuru disease is characterized by body tremors. The word “Kuru” derives from the Fore (a language spoken in Papua New Guinea), and the word “kuria” (shaking), used to describe the tremors caused by this illness. Kuru is also manifested with uncontrollable laughter, which gives the ailment another name, “laughing sickness”.

Prion, Kuru and
Cannibalism

Among the people of Papua New Guinea, the incidence of Kuru was the highest among those that ate the brains of the deceased. It was demonstrated that Kuru is caused by prion particles, which have their highest concentration in the brains of the sick. The same prion particle, discovered by Dr. Stanley Prusiner, which causes Creutzfeldt-Jakob disease, it is also the causative agent responsible for the Kuru epidemic. Like all neurodegenerative diseases caused by prions, including Alzheimer’s, Kuru is incurable at present.

Prion-Like Transmission and
Alzheimer Disease

Alzheimer’s
disease is the main cause of dementia, memory loss, and cognitive decline in
elderly patients. The illness’ symptoms start gradually, but worsen quickly
later on, severely affecting a patient’s thinking capacity and behavior. The
brain of Alzheimer’s patients shows significant damage, with remarkable loss of
neurons, as the overall brain size shrinks.

After
two decades of intense basic and clinical research, a new hypothesis to explain
the mechanism responsible for Alzheimer’s disease has emerged. Based on results
obtained from multiple experimental models, it has been demonstrated that
amyloid-beta, the same protein molecule forming aggregate deposits in the brain
known as “amyloid-beta plaques”, gives rise to smaller peptides known as “toxic
oligomers”, which behave in the same fashion as a Prion particle. These
prion-like molecules have been shown to be responsible for the toxic effects
responsible for killing neurons in the brain of Alzheimer’s patients. An
amyloid-beta toxic oligomer or “amyloid-beta prion” acquires an aberrant
conformation (shape) and it is capable of converting normal oligomers into
disease causing “amyloid-beta prions”. These prions are capable of propagating
the disease from neuron to neuron, which gradually results in neuronal loss and
memory impairment. This type of transmission is similar to what occurs in the
brain of patients suffering from Creutzfeldt-Jakob and Kuru diseases.

Despite the significant
progress made to identify the cause of Alzheimer’s disease, finding a cure for
this illness remains today as one of the most difficult challenges for the
biotechnology and pharmaceutical industries. It is common belief among experts
that a “disease-modifying drug therapy” for Alzheimer’s patients has the
potential to become the largest blockbuster medicine in the history of the
industry. Thus far, all attempts to develop such a candidate medicine have
resulted in clinical trial failures. Experts believe that the main obstacle to
finding a cure has been not knowing what causes this terrible illness.

Research – Trovagene (TROV) – Data displays room for improvement

Wednesday, February 20, 2019

Trovagene Inc. (TROV)

Room for improvement in early prostate cancer data.

TrovaGene Inc is a
US-based life science company which focuses on the development and
commercialization of a proprietary molecular genetic detection technology for
use in pharmaceutical development, clinical research and medical testing across
a variety of clinical disciplines, including oncology and virology. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

RATING: OUTPERFORM

  • ASCO GU Data
    Presentations.
     The company presented early unfavorable data from the Phase 2 Study of Onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer at the Genitourinary Cancers Symposium on February 14.  The clinical benefit  in patients was determined by the prostate-specific antigen (PSA) level and reduction was observed only transiently.
  • Adjusted Dosing Schedule. We believe the adjustment in dosing schedule and levels is not uncommon in early stages of drug development, The company intends to open a second arm, reducing the dose cycle to 14 days from 21 days t…


    GO TO FULL REPORT




    Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Dyadic (DYAI) – SEC filing on track

Wednesday, February 20, 2019

Dyadic International Inc. (DYAI)

SEC filing on track; pursuit towards Nasdaq Up-listing.

Dyadic International
Inc. is a biotechnology company developing a proprietary expression platform to
manufacture of biologic products. The company is employing C1 technology, part
of a fungi expression system, to produce variety of modalities of biologic
products, including vaccines, oncolytic viruses, monoclonal and bispecific
antibodies, as well as biosimilars.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

RATING: OUTPERFORM

  • Now an SEC Filing company. Dyadic International announced the effectiveness of Form 10, filed with the Securities and Exchange Commission (SEC) on February 12, 2019. 
  • Nasdaq Uplisting. The company is pursuing to have its common stock listed on the NASDAQ Capital Markets Exchange. The SEC filing is a positive accomplishment moving towards the uplisting. Dyadic is required to maintain a mini…


    GO TO FULL REPORT




    Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – ProMIS Neurosciences (PMN:CA) – Initiation Report

Friday, February 15, 2019

ProMIS Neurosciences (PMN:CA)

ProMIS Initiation Report.

ProMIS Neurosciences,
Inc., a development stage biotech company, discovers and develops precision
medicine therapeutics for the treatment of neurodegenerative diseases,
primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its
proprietary target discovery engine is based on the use of two complementary
techniques. 

Cosme Ordoñez, M.D., Ph. D.

, Life Sciences Analyst, Noble Capital Markets, Inc.

RATING: OUTPERFORM

  • Coverage initiation. We are initiating coverage on ProMIS Neurosciences, Inc. with an Outperform Rating and a $1.00 target price. 
  • A unique technology. ProMIS has developed a unique technology to identify disease specific conformational epitopes, which allows the Company to discover antibodies targeting neurodegenerative diseases such as Alzhei…


    GO TO FULL REPORT




    Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

News – Polo-like kinases inhibitors are novel drug targets of cancer therapeutics

Polo-like kinases inhibitors are novel drug targets of cancer therapeutics

(Note: all the sources listed in the “Balanced” section) 

We will lose an estimated 9.6 million people due to cancer this year according to the World Health Organization.  The report, published in September, also says that cancer is now the second leading cause of death across the globe.

Doctors today are turning to Polo-like kinases in order to develop anti-cancer drugs.

According to an article in the health journal Molecular Cell , “about 150 kinase-targeted drugs are currently being tested in clinical trials, followed by many kinase-specific inhibitors advancing in preclinical stage of drug development.”

News – Can manufacturing keep up with demand for biologic drugs?

Can manufacturing
keep up with demand for biologic
drugs?

Biologic drugs or “biologics” are therapeutic agents extracted or partially synthesized from biological sources, and the demand for them is growing. 

This year alone 37% of the drugs the U.S. Food & Drug Administration approved have been biologics and they make up an estimated 70% of the top selling drugs in the marketplace.

Now, the manufacturers are facing a critical decision.  Do they keep sailing the current course when it comes to production?  Or do they seek out new ways to improve?

News – HIV – Could there be a cure?

Finding a cure for HIV infection; promise or reality?

(Note: all the sources listed in the “Balanced” section)

Anti-retroviral therapy (ART), or highly-active-antiretroviral
therapy (HAART), is effective in halting progression of HIV infection. However,
the HIV virus, despite of the treatment, remains hidden in the human body. In
2017, existing medications for the treatment of HIV infection such as Gilead’s
Genvoya and Merck’s Isentress had annual sales of $3.67 billion and $1.2 billion,
respectively. Notwithstanding their commercial success, these medicines do not
cure the disease. The HIV virus often remains hidden in the human body in
reservoirs such as dendritic cells, macrophages, and CD4+
lymphocytes. Since HIV was first detected in 1983, the medical community have
intensively searched for a cure for HIV infection.

The
Story of the Berlin Patient. 
In 2007, Timothy Ray Brown, an American studying in Berlin,
Germany, was treated with a hematopoietic stem cell transplant. Two years
earlier, Mr. Brown had been diagnosed with a type of blood cancer known as acute
myeloid leukemia (AML). Besides its cancer diagnosis, Timothy was infected with
the Human Immunodeficiency Virus (HIV). Dr. Gero Hütter, a German doctor from
the Charité Hospital, Berlin University of Medicine, performed the transplant. At
the time, Dr. Hütter had never treated an HIV patient before Timothy, but he
had learnt about a rare genetic mutation causing natural resistance to HIV
infection. Based on this information, Dr. Hütter found a stem-cell donor
carrying this specific mutation. He performed the transplant on Mr. Brown using
these mutated cells.

The procedure resulted in a surprising outcome as Timothy’s HIV
infection disappeared after the transplant. The HIV virus could not be detected
on his blood, not even with the most sensitive diagnostic techniques such
polymerase chain reaction (PCR) methods. Timothy Ray Brown was cured of his HIV
infection. He became famous in the medical community. Timothy is now known as
the Berlin patient (https://www.youtube.com/watch?v=f6DXqGZt_Fw). The story of the Berlin patient triggered significant interest in both academy and industry, setting off a golden rush to find a sterilizing cure for HIV infection. Timothy’s transplant treatment was done from a donor carrying a mutation in a gene known as CCR5, which happens to be the site of entry utilized by HIV virus to infect immune system cells (New England Journal of Medicine 2009, 360, 692-698). The CCR5 protein receptor is expressed on the surface of lymphocytes T, which are the predominant target cell for the virus. Two cell receptors, CD4+ and CCR5, are utilized by HIV to enter the cell. The virus cannot enter and infect cells with a defective CCR5 receptor. As a result, HIV cannot find a home, the patient’s viral load gradually decreases, and eventually the virus fizzles out. This is probably what transpired during Mr. Brown’ treatment procedure. The fact of the matter is that the virus became undetectable in Timothy’s body. He stopped taking any medication for HIV, although he continued to undergo treatment for his blood cancer. Since then, Timothy has remained HIV negative. He has been cured from his HIV infection.

News – Alzheimer’s – The race to a better treatment

Alzheimer’s; will an effective treatment emerge?

(Note: all the sources listed in the “Balanced” section)  

Alzheimer’s disease is the main cause of dementia, memory loss,
and cognitive decline in elderly patients. The illness’ symptoms start
gradually, but worsen quickly later on, severely affecting thinking and
behavior of patients. Alzheimer’s disease remains as one of the most difficult
challenges for the biotechnology and pharmaceutical industries. Undoubtedly,
the commercial opportunity for a “disease-modifying drug therapy” for
Alzheimer’s patients has the potential to become the largest blockbuster drug
in the history of both industries. Thus far, all attempts to develop such a
candidate medicine have resulted in clinical trial failures.

News – Cancer – Gene therapy, what the future holds

Cancer gene therapy – past, present & future

(Note: all the sources listed in the “Balanced” section) 


To the medical community, the premise of
replacing mutated genes with normal corresponding genes have been widely viewed
as a promising treatment for cancer. “Oncogenes” are genes known to promote
malignant tumor growth, whereas “tumor suppressor genes” have the opposite
function as they inhibit tumor formation. The scientific theory of replacing a
mutated tumor suppressor gene for its corresponding normal copy is robust, with
scientists, physicians and biotech entrepreneurs agreeing that the pursue of
gene therapy approaches for the treatment of cancer should become a common goal
(https://www.youtube.com/watch?v=2NVBsPfOtT8).

In spite of this enthusiasm, not all investors
are fully convinced, as some remain skeptical about the prospects for cancer
gene therapy.